Roche’s Second Actemra Pivotal Trial Supports Novel IL-6 Inhibitor In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche expects two additional Phase III clinical trials evaluating tocilizumab to report later this year.
You may also be interested in...
Actemra OPTION Trial Shows Benefit In RA Patients In Combination With Methotrexate
Phase III trial, published in The Lancet, supports the use of Roche’s interleukin-6 inhibitor for rheumatoid arthritis.
Actemra OPTION Trial Shows Benefit In RA Patients In Combination With Methotrexate
Phase III trial, published in The Lancet, supports the use of Roche’s interleukin-6 inhibitor for rheumatoid arthritis.
Roche Files BLA For Rheumatoid Arthritis Therapy Actemra
The novel interleukin-6 receptor-inhibiting mAb has a projected September 2008 action date.